Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4
Brief Summary: GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).


Options:
A: Arm Label: GSK2336805; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK2336805 Matching Placebo | Arm Label: GSK2336805 + pegylated interferon alfa-2a + ribavrin; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: Placebo + pegylated interferon alfa-2a + ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alfa-2a, Drug: Ribavirin, Drug: GSK2336805 Matching Placebo | Intervention Type: DRUG; Name: GSK2336805; Assigned to Arm(s): GSK2336805, GSK2336805 + pegylated interferon alfa-2a + ribavrin | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: GSK2336805 Matching Placebo; Assigned to Arm(s): Placebo, Placebo + pegylated interferon alfa-2a + ribavirin
B: Arm Label: Part 1: Single Dose Escalation in Healthy Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805 10mg, Drug: GSK2336805 30mg, Drug: GSK2236805 100mg, Drug: GSK2236805 200mg | Arm Label: Part 2: Repeat Dose Escalation in Healthy Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2236805 10mg, Drug: GSK2236805 dose to be determined up to 100mg | Arm Label: Part 3: Single Dose Escalation in HCV Infected Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2236805 5mg, Drug: GSK2236805 30mg, Drug: GSK2236805 100mg | Intervention Type: DRUG; Name: GSK2336805 10mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2336805 30mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 100mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 200mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 10mg; Assigned to Arm(s): Part 2: Repeat Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 dose to be determined up to 100mg; Assigned to Arm(s): Part 2: Repeat Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 5mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects | Intervention Type: DRUG; Name: GSK2236805 30mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects | Intervention Type: DRUG; Name: GSK2236805 100mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: TMC435/PR; Type: EXPERIMENTAL; Interventions: Drug: TMC435 | Arm Label: TVR/PR; Type: ACTIVE_COMPARATOR; Interventions: Drug: TVR | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435/PR | Intervention Type: DRUG; Name: TVR; Assigned to Arm(s): TVR/PR

Answer: A